Functional Assessment Using QFR for the Revascularization of Non-Culprit Lesions in AMI Patients

Nowadays, evidence from studies and meta-analyses has demonstrated the benefits of complete revascularization compared to culprit-vessel-only revascularization in patients with acute myocardial infarction (AMI). The identification and treatment of non-culprit lesions can be guided by conventional angiography, intracoronary imaging, or coronary physiology; the optimal modality, however, is still unclear.

IAM

Quantitative flow ratio (QFR) is a type of functional assessment derived from angiography that doesn’t require a coronary guidewire. Various studies have assessed this tool, including FAVOR III (Functional Assessment by Virtual Online Reconstruction), which demonstrated that QFR-based revascularization reduces the incidence of major cardiovascular events. However, the role of QFR in treating non-culprit lesions in AMI patients remains uncertain.

The objective of this multicenter, randomized study was to assess the predictive capability of QFR for adverse events and to evaluate the non-inferiority of QFR-guided management for treating non-culprit lesions.

The primary endpoint (PEP) was a composite of cardiac death, target vessel myocardial infarction (TVMI), and ischemia-driven target vessel revascularization (id-TVR). The secondary endpoint (SEP) included the individual components of the PEP.

The FIRE (Functional Assessment in Elderly MI Patients With Multivessel Disease) study randomized 1145 AMI patients into two groups: culprit-vessel-only revascularization (n=725) and complete physiology-guided revascularization (n=720). The mean age of the participants was 81 years, and most subjects were men. The most frequent clinical presentation was non-ST segment elevation MI (about 60%), followed by ST segment elevation MI.

Read also: EuroPCR 2024 | Self-Expanding Valves (ACURATE Neo2) vs. Balloon-Expandable Valves (Sapien 3 Ultra): 1-Year Follow-up Results.

The most frequently affected vessel was the left anterior descending artery, followed by the right coronary artery, the circumflex artery, and the left main coronary artery. QFR was measured in 903 non-culprit vessels of 685 patients in the culprit-only group. In total, 366 (40.5%) of the non-culprit vessels showed a QFR value ≤0.80, with a significantly higher incidence of the PEP (22.1% vs. 7.1%; P <0.001).

A QFR ≤0.80 emerged as an independent predictor of the PEP (hazard ratio [HR]: 2.79; 95% confidence interval [CI]: 1.64-4.75). In the complete revascularization group, QFR was used in 320 (35.2%) non-culprit vessels to guide revascularization. There were no significant differences in the PEP when comparing the treatments of non-culprit vessels guided by QFR-based functional assessment (HR: 0.57; 95% CI: 0.28-1.15).

Conclusion

This study demonstrated that QFR can be safely used to identify non-culprit lesions requiring revascularization in AMI patients with multivessel disease.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: QFR for the Revascularization of Nonculprit Vessels in MI Patients Insights From the FIRE Trial.

Reference: Andrea Erriquez, MD et al J Am Coll Cardiol Intv 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....